Egyptian International Pharmaceutical Investments's quarterly market cap
increased
from Jun. 2025 (E£8,536 Mil) to Sep. 2025 (E£11,182 Mil) and
increased
from Sep. 2025 (E£11,182 Mil) to Mar. 2026 (E£13,122 Mil).
Egyptian International Pharmaceutical Investments's annual market cap
increased
from Dec. 2022 (E£3,621 Mil) to Dec. 2023 (E£5,430 Mil) and
increased
from Dec. 2023 (E£5,430 Mil) to Dec. 2024 (E£6,829 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Egyptian International Pharmaceutical Investments's Enterprise Value for Today is E£23,955 Mil.
Egyptian International Pharmaceutical Investments (CAI:PHAR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Egyptian International Pharmaceutical Investments Market Cap Related Terms
Egyptian International Pharmaceutical Investments Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Market Cap Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Market Cap vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Market Cap of E£14,886 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Egyptian International Pharmaceutical Investments and its competitors. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #477 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Egyptian International Pharmaceutical Investments' Market Cap too high?
Egyptian International Pharmaceutical Investments' current Market Cap is E£14,886 Mil. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #477 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #477 out of 1022 companies for Market Cap. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median Market Cap is 221.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 221.60, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Market Cap is 221.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Market Cap is E£14,886 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.73, compared to a current price of E£88.21 — trading 47.7% above its estimated fair value. The current Market Cap is E£14,886 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Market Cap is E£14,886 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£88.21 is trading 47.7% above its estimated GF Value™ of E£59.73.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Market Cap: E£14,886 Mil
GF Value™: E£59.73 vs. price of E£88.21 (47.7% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score
Get the complete analysis for CAI:PHAR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
